After the first pilot study on the induction of immune tolerance to myelin antigens, multicenter, randomized, conducted a double-blind, placebo-controlled study by oral administration of myelin. This study was conducted of the third stage in 14 centers in the United States and Canada. It included more than 500 patients with RRMS (EDSS scores of 4.5 or less), stratified by gender and phenotype DR2 (because we have observed in a previous study, men or HLA-DR2 without tend better to treatment). The primary endpoint was to study two-year relapse rate, while ultimately included secondary MRI. The results of this study showed no great benefit of oral myelin (MyloralMD) compared with placebo.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.